Form 8-K - Current report:
SEC Accession No. 0000950170-25-078590
Filing Date
2025-05-29
Accepted
2025-05-29 07:00:12
Documents
12
Period of Report
2025-05-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sprb-20250528.htm   iXBRL 8-K 85753
2 EX-3.1 sprb-ex3_1.htm EX-3.1 33734
3 EX-10.1 sprb-ex10_1.htm EX-10.1 65747
  Complete submission text file 0000950170-25-078590.txt   323429

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sprb-20250528.xsd EX-101.SCH 31809
14 EXTRACTED XBRL INSTANCE DOCUMENT sprb-20250528_htm.xml XML 4910
Mailing Address 611 GATEWAY BOULEVARD, SUITE 740 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 740 SOUTH SAN FRANCISCO CA 94080 (415) 655-4168
SPRUCE BIOSCIENCES, INC. (Filer) CIK: 0001683553 (see all company filings)

EIN.: 812154263 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39594 | Film No.: 25997646
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)